Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
Analysis by Public Health England (PHE) has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
The real-world data, which were announced in a June 14, 2021 press release, have shown that two doses of the Pfizer-BioNTech vaccine are 96% effective at preventing hospitalization and two doses of the Oxford-AstraZeneca vaccine are 92% effective against hospitalization due to the Delta variant of COVID-19. These results are comparable with the efficacy found against hospitalization from the Alpha variant of the virus.
As of yet, the level of protection offered by the vaccines against mortality from the Delta variant is not known, but further work is underway to establish these data also. However, it is anticipated that the vaccines’ level of protection against mortality will also be high, as has been the case with other variants.
“These hugely important findings confirm that the vaccines offer significant protection against hospitalization from the Delta variant,” said Mary Ramsay, head of Immunisation at PHE, in the press release. “The vaccines are the most important tool we have against COVID-19. Thousands of lives have already been saved because of them.”
Source: PHE
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.